Bristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

(Low)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/01/2023 - 06:59 AM

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Morgan Stanley 21^st Annual Global Healthcare Conference in New York City on Monday, September 11, 2023. Giovanni Caforio, M.D., board chair and chief executive officer, and Chris Boerner, Ph.D., executive vice president and chief operating officer, will answer questions about the company during a fireside chat at 8 a.m. EDT.

Investors and the general public are invited to listen to a live webcast of the session here. An archived edition of the session will be available following the session’s conclusion.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

corporatefinancial-news

View source version on businesswire.com: https://www.businesswire.com/news/home/20230831671626/en/

Media:
media@bms.com

Investors:
investor.relations@bms.com

Source: Bristol Myers Squibb

Keep reading

More on BMY

All BMY news

Trending in the feed

ALEC

Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases Open the live feed